-

SK Capital Partners Appoints Jason Grapski as Managing Director, Portfolio Excellence

NEW YORK--(BUSINESS WIRE)--SK Capital Partners (“SK Capital”), a private investment firm focused on the material sciences, specialty ingredients, and life sciences sectors, announced today that Jason Grapski has joined the firm as Managing Director, Portfolio Excellence. In this position, Mr. Grapski will lead the firm’s approach to portfolio company improvement, focusing on enhancing execution and accelerating the realization of each company’s strategic, operational and financial objectives.

Mr. Grapski joins SK Capital from Berkshire Partners, where he was an Operating Partner in their Portfolio Support Group for over a decade. Earlier in his career, he was a Senior Vice President at Univar, focusing on strategy, mergers and acquisitions, and continuous improvement, and a Partner at McKinsey & Company. Mr. Grapski received a B.S. from MIT and a Ph.D. from the University of Delaware, both in Chemical Engineering.

"I am excited to join SK Capital as Managing Director, Portfolio Excellence and look forward to working alongside the investment teams, operating resources, and executive leadership teams across the firm’s portfolio companies to translate investment theses into high-velocity execution plans,” said Mr. Grapski.

Barry Siadat, Co-Founder and Managing Director at SK Capital Partners, commented, “Jason brings a unique combination of operational leadership, strategic insight, team building and hands-on execution experience. We are excited to welcome him as we continue to strengthen our differentiated approach to value creation.”

About SK Capital:

SK Capital is a transformational private investment firm with a disciplined focus on the material sciences, specialty ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital manages funds with over $8.5 billion in aggregate commitments. For more information, please visit www.skcapitalpartners.com.

Contacts

Jeremy Milner
jmilner@gregoryagency.com
(401) 862-9422

SK Capital Partners


Release Versions

Contacts

Jeremy Milner
jmilner@gregoryagency.com
(401) 862-9422

More News From SK Capital Partners

Valtris Specialty Chemicals Announces New Chief Human Resources Officer

INDEPENDENCE, Ohio--(BUSINESS WIRE)--Valtris Specialty Chemicals, a leading global manufacturer of a comprehensive portfolio of specialty additives, announced today the appointment of Clint Shephard as the company’s new Chief Human Resources Officer. Mr. Shephard will play a key role in leading the company’s global talent strategy. Mr. Shephard will be based in the company’s new office in Midland, Michigan. Mr. Shephard most recently served as Senior Director of Human Resources at Myers Industr...

SK Capital Partners Completes the Sale of Phoenix Flavors & Fragrances to Turpaz Industries

NORWOOD, N.J.--(BUSINESS WIRE)--Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the material sciences, specialty ingredients, and life sciences sectors, announced today that it has completed the sale of Phoenix Flavors & Fragrances Inc. (“Phoenix” or the “Company”) to Turpaz Industries Ltd (TLV: TRPZ), a global developer, manufacturer, and marketer of specialty fragrance, flavor, and natural ingredient solutions for consumer and in...

SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG

NEW YORK--(BUSINESS WIRE)--Affiliates of funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today they have completed the sale of Noramco, Extractas Biosciences, and Purisys of the Noramco Group (“Noramco” or the “Company”) to Siegfried Holding AG (SIX: SFZN; “Siegfried”), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry....
Back to Newsroom